Corvus Capital Limited /
Conduit Pharmaceuticals Limited
CDT Equity sells Conduit Pharmaceuticals subsidiary to Corvus Capital
Source for the buyer and target: CDT Equity Inc.
For the buyer and target.
“On December 8, 2025, CDT Equity Inc. (the “Company”) and Corvus Capital Limited (“Corvus”) entered into a Sale and Purchase Agreement (the “Agreement”) for the issuance of all of the outstanding shares of Conduit Pharmaceuticals Limited (“CPL”) held of record by the Company (the “CPL Share”), 224,800 shares of common stock, par value $0.0001 per share (the “Common Stock”) of the Company (the “CDT Shares”), and 3,685,815 pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”) collectively to Corvus.”
Published 12 Dec 2025
Open the sourceWhat happened
CDT Equity Inc. sold Conduit Pharmaceuticals Limited to Corvus Capital Limited, a wholly-owned subsidiary of the Company’s Chief Executive Officer. The sale included potential liability associated with ongoing litigation. [01]
The $7,000,000 settlement amount was satisfied through the issuance of CDT Equity shares and pre-funded warrants. [01]
The source
Everything on this page comes from the source below, quoted word for word.
CDT Equity sells Conduit Pharmaceuticals subsidiary to Corvus Capital
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly